Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients
Abstract Sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) is a new immune checkpoint molecule and its role of primary central nervous system lymphoma (PCNSL) tumor microenvironment has been unclear. We explored the Siglec-15 and programed death-ligand 1 (PD-L1) expression in tumor tissu...
Guardado en:
Autores principales: | , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d68bef7cadce40c1baa011d3079d925c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:d68bef7cadce40c1baa011d3079d925c |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:d68bef7cadce40c1baa011d3079d925c2021-12-02T14:01:23ZSialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients10.1038/s41598-020-79742-92045-2322https://doaj.org/article/d68bef7cadce40c1baa011d3079d925c2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79742-9https://doaj.org/toc/2045-2322Abstract Sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) is a new immune checkpoint molecule and its role of primary central nervous system lymphoma (PCNSL) tumor microenvironment has been unclear. We explored the Siglec-15 and programed death-ligand 1 (PD-L1) expression in tumor tissues and analyzed the association between the expression of these molecules and overall survival in newly diagnosed PCNSL. A total of 60 patients diagnosed with diffuse large B-cell lymphoma in PCNSL were included in this study. The Siglec-15 and PD-L1 expression on tumor cells, intratumoral macrophages and peritumoral macrophages were immunohistochemically evaluated. The expression of Siglec-15 and PD-L1 was greater in macrophages than in tumor cells. Regarding peritumoral macrophages, the number of Siglec-15-positive samples (n = 24) was greater than the number of PD-L1-positive samples (n = 16). A multivariate Cox analysis showed that the Siglec-15 positivity of peritumoral macrophages and performance of high-dose methotrexate-based chemotherapy were independent predictors of overall survival (hazard ratio: 0.295 and 0.322, respectively). The Kaplan–Meier survival curves showed that patients with Siglec-15-positive peritumoral macrophages had longer overall survival than those with Siglec-15-negative peritumoral macrophages (median overall survival: 3018 days and 746 days, respectively; p = 0.0290). Our findings indicate that the expression of Siglec-15 on peritumoral macrophages induces a favorable outcome in PCNSL patients.Hirotaka FudabaYasutomo MomiiTaisei HirakawaKouhei OnishiDaigo AsouWataru MatsushitaYukari KawasakiKenji SugitaMinoru FujikiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Hirotaka Fudaba Yasutomo Momii Taisei Hirakawa Kouhei Onishi Daigo Asou Wataru Matsushita Yukari Kawasaki Kenji Sugita Minoru Fujiki Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients |
description |
Abstract Sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) is a new immune checkpoint molecule and its role of primary central nervous system lymphoma (PCNSL) tumor microenvironment has been unclear. We explored the Siglec-15 and programed death-ligand 1 (PD-L1) expression in tumor tissues and analyzed the association between the expression of these molecules and overall survival in newly diagnosed PCNSL. A total of 60 patients diagnosed with diffuse large B-cell lymphoma in PCNSL were included in this study. The Siglec-15 and PD-L1 expression on tumor cells, intratumoral macrophages and peritumoral macrophages were immunohistochemically evaluated. The expression of Siglec-15 and PD-L1 was greater in macrophages than in tumor cells. Regarding peritumoral macrophages, the number of Siglec-15-positive samples (n = 24) was greater than the number of PD-L1-positive samples (n = 16). A multivariate Cox analysis showed that the Siglec-15 positivity of peritumoral macrophages and performance of high-dose methotrexate-based chemotherapy were independent predictors of overall survival (hazard ratio: 0.295 and 0.322, respectively). The Kaplan–Meier survival curves showed that patients with Siglec-15-positive peritumoral macrophages had longer overall survival than those with Siglec-15-negative peritumoral macrophages (median overall survival: 3018 days and 746 days, respectively; p = 0.0290). Our findings indicate that the expression of Siglec-15 on peritumoral macrophages induces a favorable outcome in PCNSL patients. |
format |
article |
author |
Hirotaka Fudaba Yasutomo Momii Taisei Hirakawa Kouhei Onishi Daigo Asou Wataru Matsushita Yukari Kawasaki Kenji Sugita Minoru Fujiki |
author_facet |
Hirotaka Fudaba Yasutomo Momii Taisei Hirakawa Kouhei Onishi Daigo Asou Wataru Matsushita Yukari Kawasaki Kenji Sugita Minoru Fujiki |
author_sort |
Hirotaka Fudaba |
title |
Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients |
title_short |
Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients |
title_full |
Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients |
title_fullStr |
Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients |
title_full_unstemmed |
Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients |
title_sort |
sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/d68bef7cadce40c1baa011d3079d925c |
work_keys_str_mv |
AT hirotakafudaba sialicacidbindingimmunoglobulinlikelectin15expressiononperitumoralmacrophagesisafavorableprognosticfactorforprimarycentralnervoussystemlymphomapatients AT yasutomomomii sialicacidbindingimmunoglobulinlikelectin15expressiononperitumoralmacrophagesisafavorableprognosticfactorforprimarycentralnervoussystemlymphomapatients AT taiseihirakawa sialicacidbindingimmunoglobulinlikelectin15expressiononperitumoralmacrophagesisafavorableprognosticfactorforprimarycentralnervoussystemlymphomapatients AT kouheionishi sialicacidbindingimmunoglobulinlikelectin15expressiononperitumoralmacrophagesisafavorableprognosticfactorforprimarycentralnervoussystemlymphomapatients AT daigoasou sialicacidbindingimmunoglobulinlikelectin15expressiononperitumoralmacrophagesisafavorableprognosticfactorforprimarycentralnervoussystemlymphomapatients AT watarumatsushita sialicacidbindingimmunoglobulinlikelectin15expressiononperitumoralmacrophagesisafavorableprognosticfactorforprimarycentralnervoussystemlymphomapatients AT yukarikawasaki sialicacidbindingimmunoglobulinlikelectin15expressiononperitumoralmacrophagesisafavorableprognosticfactorforprimarycentralnervoussystemlymphomapatients AT kenjisugita sialicacidbindingimmunoglobulinlikelectin15expressiononperitumoralmacrophagesisafavorableprognosticfactorforprimarycentralnervoussystemlymphomapatients AT minorufujiki sialicacidbindingimmunoglobulinlikelectin15expressiononperitumoralmacrophagesisafavorableprognosticfactorforprimarycentralnervoussystemlymphomapatients |
_version_ |
1718392173235273728 |